Samarth Kulkarni - 14 Mar 2026 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role: Chief Executive Officer, Director
Signature: Elizabeth Ryland Waldinger, attorney-in-fact
Issuer symbol: CRSP
Transactions as of: 14 Mar 2026
Net transactions value: -$499,443
Form type: 4
Filing time: 17 Mar 2026, 17:35:20 UTC
Previous filing: 12 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Kulkarni Samarth	Chief Executive Officer, Director	C/O CRISPR THERAPEUTICS, 105 WEST FIRST STREET, BOSTON	Elizabeth Ryland Waldinger, attorney-in-fact	17 Mar 2026	0001682019

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CRSP	Common Shares	Options Exercise		+20,625	+8.8%		256,183	14 Mar 2026	Direct	F1, F2
transaction	CRSP	Common Shares	Sale	$499,443	-10,349	-4%	$48.26	245,834	16 Mar 2026	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CRSP	Restricted Stock Units	Options Exercise		-20,625	-25%		61,875	14 Mar 2026	Common Shares	20,625		Direct	F1, F2, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.
F2	Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F3	Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
F4	This restricted stock unit award was granted on March 14, 2025 with respect to 82,500 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029.